Member Info for E_AL

Another big buy

11:17:31 210.442 95,000 £199.92k

WOW

10:57:18 205.00 BUY 1,181,143 £2m

Same here. I can sell all of my position in one go but had to buy 6x £1750 chunks to top up

Climbing back up after flushing out yesterday's traders

Nice buy just gone through:

09:30:02 225.92 65,547 148.08k

missed the cheap entry earlier ? ;)

Watch the bounce here tomorrow

MM MREX is on the BID @ 19!! its about to breakout

Nice buying pressure building here & another attempt to break 20p ;)

Solid BID on the L2 atm, the share price is about to move up

Solid BID on Level 2 & it looks like it will turn blue soon

The BID looks much better now and ready to move

Interesting update apart from the troubles in Trinidad

No placing. Check the interim results from last week:

“ Successful Reserve Based Lending facility (RBL) redetermination in June (a semi-annual recalculation), confirming US$27 million (£19.5 million) of debt capacity and headroom of US$8.8 million (£6.4 million).”

“ our forecast shows that the Group will have sufficient financial headroom to meet its financial covenants for the 12 months from the date of approval of the financial statements.”

EUA currently has an overvalued Mcap, unlike IGAS

Buying pressure building and the BID looks really good on L2

BUY/Sell - almost 3:1

# Trades 76

Vol. Sold 26,007
Sold Value £81.51k

Vol. Bought 68,476
Bought Value £214.60k

GLP doesnt have the balls to mention the name of Innova, let alone including them in their case. Innova will instantly sue them for damaging the company's reputation and push GLP into bankruptcy via a never ending lawsuits even though we all know the rubbish quality of Innova's products.

Good to see Abingdon fighting back, they replied in a tweet to GLP rubbish:

“ We continue to ask @GoodLawProject to refrain from making unsubstantiated assertions that are damaging to our Company – read our corrections to their factual inaccuracies here: https://www.abingdonhealth.com/app/uploads/2021/08/2021.05.04-Letter-to-Rook-Irwin-Sweeney-LLP-V4.pdf “

“ We've also published our ‘Detailed Grounds for Resistance’ to ensure @GoodLawProject's factual inaccuracies are addressed – you can read it here: https://www.londonstockexchange.com/news-article/ABDX/disclosure-of-detailed-grounds-for-resistance/15091138 “

https://twitter.com/abingdon_health/status/1440351314001625100

Share price trend tested the 290 support twice (double bottom) and up she goes #Bullish ;)

"The product has successfully completed technical transfer to manufacture and is now in FULL manufacture "

Being Biosure EXCLUSIVE manufacturer, Abingdon is currently manufacturing the testing kit for Biosure to sell worldwide!

Then two weeks later the company signed an exclusive deal with Biosure to be the exclusive worldwide manufacturer of the CE marked COVID-19 IgG antibody self test. The product has successfully completed technical transfer to manufacture following a pilot production run and is now in full manufacture at Abingdon's expanded manufacturing facilities at York and Doncaster. It is the only approved COVID-19 IgG antibody self test in the UK at the moment!

"23 August 2021: Abingdon Health plc (AIM: ABDX) a leading international developer and manufacturer of high quality and effective rapid tests, announces the launch today of the BioSURE COVID-19 IgG Antibody Self Test. In July 2021, Abingdon announced that it had signed an exclusive manufacturing agreement with BioSure (UK) Limited ("BioSure"), a UK company specialising in the provision of rapid in-vitro diagnostic testing solutions, including self-testing.



This new test, for which BioSure is the legal manufacturer, has been CE marked specifically for self-testing. The test uses a fraction of a drop of finger-prick blood (2.5uL) with results in 20 minutes. This allows individuals to know and monitor their own antibody status pre-vaccination, post vaccination and following infection with the SARS-CoV-2 virus. It will be particularly useful as populations worldwide continue to be vaccinated to monitor the effectiveness of an individual's immunity status. This will have utility alongside potential booster vaccinations. Abingdon will be the exclusive worldwide manufacturer for the product.



The product has successfully completed technical transfer to manufacture following a pilot production run and is now in full manufacture at Abingdon's expanded manufacturing facilities at York and Doncaster under the Company's ISO13485:2016 quality management system. Technical transfer is the process whereby three or more independent production runs are manufactured, at increasing scale, and validated to illustrate the product is suitable for mass manufacture."